Press Releases

Study Aims to Assess Potential for BXQ-350 to Reduce the Intensity and/or Duration of Chemotherapy-Induced Peripheral Neuropathy (CIPN), a Prevalent Limitation of Existing Chemotherapies FOR IMMEDIATE RELEASE Covington, KY, October 18, 2022 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing biologics for the treatment of cancer and neuropathy, announced today that the first adult patient has been dosed in the Pilot Proof of [...]

FOR IMMEDIATE RELEASE [Covington, KY--- 14 September 2022] Bexion Pharmaceuticals, Inc., a mid-stage clinical biopharmaceutical company developing a new generation of biologic immunotherapy to treat solid tumor cancers and Chemotherapy Induced Peripheral Neuropathy (CIPN), announced today that an abstract submitted for an in-person session at the EANO annual meeting to be held in Vienna, Austria from September 15-18, 2022 has been chosen for [...]

FOR IMMEDIATE RELEASE [Covington, KY---June 13, 2022] Bexion Pharmaceuticals, Inc., a mid-stage clinical biopharmaceutical company, announced today that two abstracts submitted for an in-person session at the IPSNO annual meeting to be held in Hamburg, Germany, June 12-15, 2022 has been chosen for poster presentation. ISPNO is the largest international scientific meeting of multidisciplinary professionals in research, diagnosis, treatment, and rehabilitation of children [...]

Seasoned BIO/Pharma Executive adds finance, strategic capital access and public market readiness to the management team FOR IMMEDIATE RELEASE [Covington, KY---June 2, 2022l] Bexion Pharmaceuticals, Inc., a mid-stage biopharmaceutical company developing innovative therapies for cancers and chemotherapy induced peripheral neuropathy (CIPN), announced today that Ms. Joyce LaViscount has joined the Company’s leadership team as Chief Financial Officer (CFO). Ms. LaViscount brings over 30 [...]

FOR IMMEDIATE RELEASE [Covington, KY---May 10, 2022 ] Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for the CIMT annual meeting to be held in Mainz, Germany, May 10-12, 2022 has been chosen for poster presentation. Every year, the CIMT Annual Meeting connects the global cancer immunotherapy community in the heart of Europe. As the largest meeting focused [...]

The new leadership roles support the company’s momentum in becoming the leader in developing and commercializing therapeutics based on exploiting the lysosome to treat challenging solid tumors as well as chemotherapy-induced peripheral neuropathy (CIPN). FOR IMMEDIATE RELEASE [Covington, KY---February 2, 2022] Bexion Pharmaceuticals, a clinical stage biopharmaceutical company, today announced key leadership changes, including the appointment of Richard “Scott” Shively as the Company’s [...]